NEW YORK (GenomeWeb News) – Quest Diagnostics today pre-announced third quarter earnings results that are expected to fall short of consensus Wall Street estimates.

For the three months ended Sept. 30, the company said that revenues from continuing operations are anticipated to be $1.79 billion, a 2 percent dip from the year-ago period and below analyst expectations of $1.84 billion. Its earnings per share is expected to be $2.66, up from $.98 a year ago. On an adjusted basis EPS is estimated at $1.02, short of Wall Street estimates of $1.20.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

 Senator Lamar Alexander (R-Tenn.), who chairs the Senate health committee, will be retiring at the end of his term, Stat News reports.

UCSF researchers find that having two X chromosomes may contribute to women's longer lifespans, according to Discover's D-brief blog.

The Wall Street Journal reports on the US Centers for Disease Control and Prevention's use of genetic approaches to study foodborne illnesses.

In PNAS this week: immune cell profiling of wild baboons by social status, metabolomics profiling of esophageal tumors, and more.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.